Research Highlight |
Featured
-
-
Research Highlight |
Gene-edited organoids enable sensitive assessment of peptide hormone variation
- Olivia Tysoe
-
-
Correspondence |
Reply to: Late dumping syndrome or postprandial reactive hypoglycaemic syndrome after bariatric surgery
- Emidio Scarpellini
- , Joris Arts
- & Jan Tack
-
-
Review Article |
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
The gut secretes approximately 20 active hormones with overlapping targets and actions. This Review focuses on the molecular mechanisms underlying the modulation of gut hormone release by food ingestion, obesity and the gut microbiota.
- Fiona M. Gribble
- & Frank Reimann
-
Review Article |
Motilin: from gastric motility stimulation to hunger signalling
Interest in motilin is growing, as several studies have shown its relevance in the control of hunger and regulation of food intake in both health and disease. The current state of knowledge and implications for therapy are summarized in this Review.
- Eveline Deloose
- , Wout Verbeure
- & Jan Tack
-
-
Review Article |
Glucagon-like peptide 1 in health and disease
In this Review, the authors describe the physiology of glucagon-like peptide 1 (GLP1) and its role in type 2 diabetes mellitus (T2DM), the currently available and emerging GLP1 receptor agonists and their use to treat T2DM and other indications.
- Andreas Andersen
- , Asger Lund
- & Tina Vilsbøll
-
-
-
-
Review Article |
The cellular and molecular bases of leptin and ghrelin resistance in obesity
In obesity, individuals develop resistance to leptin and ghrelin, which have important functions in the neuroendocrine control of energy homeostasis. Here, Cui and colleagues discuss the mechanisms that lead to leptin and ghrelin resistance, and how they might be exploited as targets for the management and treatment of obesity.
- Huxing Cui
- , Miguel López
- & Kamal Rahmouni
-
-
-
Research Highlight |
'Runner's high' abolished by leptin signalling in dopamine neurons in the ventral tegmental area
- Tim Geach
-
Viewpoint |
The past 10 years—new hormones, new functions, new endocrine organs
In this Viewpoint, six members of our Advisory Board comment on advances in the past 10 years that have revealed new hormones, new functions for known hormones and endocrine organs and new endocrine roles for well-known organs. The authors discuss how bone was recognized as an endocrine organ, the emerging understanding of the importance of gut hormones, targeting ectopic adipose tissue and the pathogenesis and treatment of type 2 diabetes mellitus.
- Roger Bouillon
- , Daniel J. Drucker
- & Paul Zimmet
-
Year in Review |
A central role of the gut in glucose homeostasis
Metabolic surgery has been proven to be effective in inducing remission of type 2 diabetes mellitus prior to any significant weight reduction. Studies in 2013 have investigated the mechanisms of action of these procedures and have highlighted a central role of the small intestine in the effects on glucose homeostasis.
- Geltrude Mingrone
- & Lidia Castagneto-Gissey
-
Research Highlight |
FTO-associated obesity risk is linked to brain food responses via modulation of ghrelin levels
- Leah Eissing
-
Review Article |
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
The success of bariatric surgery, together with emerging data from preclinical studies, illustrates the rationale and feasibility of using two or more agonists for the treatment of obesity and type 2 diabetes mellitus (T2DM). This Review summarizes advances in the science of co-agonist therapy and mechanisms of action for combinations of endocrine hormones that enhance weight loss whilst preserving glucoregulatory efficacy in experimental models of obesity and T2DM.
- Sharon A. Sadry
- & Daniel J. Drucker
-
News & Views |
Uroguanylin—a new gut-derived weapon against obesity?
A recent report has identified uroguanylin as an endocrine signal that exerts a physiological role in energy homeostasis, adding another factor to the gut–brain axis. From a clinical point of view, several observations highlight the uroguanylin–guanylyl cyclase C pathway as a potential therapeutic target for the development of antiobesity drugs.
- Gema Frühbeck
-
Review Article |
Bowels control brain: gut hormones and obesity
The gastrointestinal tract is an important source of endocrine signals. Gut hormones such as glucagon-like peptide 1, peptide YY, and islet amyloid polypeptide act in an integrated fashion to modulate appetite and energy expenditure. This Review addresses the physiological roles of gut hormones and discusses their potential as targets for the development of novel treatments for obesity, on the basis of pharmacological mimicry of the hormonal milieu after bariatric surgery.
- Benjamin C. T. Field
- , Owais B. Chaudhri
- & Stephen R. Bloom
-
-
CAMK1D required for ghrelin-mediated food intake
Mapping neuron functions in the gut–brain axis
Gut hormones involved in bone remodelling
BAT is involved in control of satiation
High-fibre diet beneficial for T2DM
FGF21 — the cause of having a 'sweet tooth'?
Pancreatic GLP1 is involved in glucose regulation
GLP-1 directs differentiation of human embryonic stem cells